BamSEC and AlphaSense Join Forces
Learn More

Oncotelic Therapeutics Inc

OTC: OTLC    
Share price (12/20/24): $0.03    
Market cap (12/20/24): $12.3 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 4 pages This Letter, Together With the Attached Binding Term Sheet Attached Hereto, Sets Forth Our Mutual Understanding Regarding a Possible Commercial Relationship Referred to as the “Transaction” Between Mosaic Immunoengineering, Inc., a Delaware Corporation (“Mosaic”) and Oncotelic Therapeutics, Inc., a Delaware Corporation (“Oncotelic”). It Is Understood That Any Such Transaction Is Subject to Our Mutual Agreement on Terms Through a Definitive Document Entered Into by Mosaic and Oncotelic Formalizing the Transaction
12/34/56
EX-10.5
from 8-K 14 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 12 pages Oncotelic Therapeutics, Inc. 16% Convertible Unsecured Note Due , 2025
12/34/56
EX-10.3
from 8-K 11 pages Oncotelic Therapeutics, Inc. Common Stock Purchase Warrant , 2023
12/34/56
EX-10.2
from 8-K 7 pages Material contract
12/34/56
EX-10.1
from 8-K 19 pages Subscription Agreement and Investment Letter
12/34/56
EX-10.2
from 8-K 21 pages Material contract
12/34/56
EX-10.1
from 8-K 23 pages Material contract
12/34/56
EX-10.2
from 8-K 21 pages Material contract
12/34/56
EX-10.1
from 8-K 23 pages Material contract
12/34/56
EX-10.2
from 8-K 5 pages Material contract
12/34/56
EX-10.1
from 8-K 5 pages Material contract
12/34/56
EX-10.3
from 8-K 30 pages Material contract
12/34/56
EX-10.2
from 8-K 30 pages Material contract
12/34/56
EX-10.1
from 8-K 83 pages Material contract
12/34/56
EX-10.2
from 8-K 5 pages Unsecured Convertible Promissory Note
12/34/56
EX-10.1
from 8-K 8 pages Unsecured Convertible Note Purchase Agreement
12/34/56
EX-10.3
from 8-K 5 pages Material contract
12/34/56
EX-10.2
from 8-K 19 pages Promissory Note
12/34/56
EX-10.1
from 8-K 21 pages Securities Purchase Agreement
12/34/56